Toward a More Nuanced Science Journalism
By Gina Maranto, Biopolitical Times guest contributor
| 05. 29. 2011
Last week, Chicago Tribune reporter Monica Eng wrote about the latest chapter in the debate over genetically modified foods: their unavoidable creep into spaces and places assumed to be GM-free. Eng's counterintuitive lede describes anti-GMO protestors improbably marching outside a Whole Foods – a sign of just how bad the situation has gotten, when even purveyors of organics can't guarantee untainted fare.
The online version features several sobering visuals: a graph showing the disquieting rise in GM soy and corn production over the last decade (such plants now represent 93% and 86% of the US harvest, respectively); a map highlighting states currently deliberating policies to label GM foods; a table listing some of the 40 countries that currently require such labeling. Eng summarizes the industry and environmental health arguments, provides the obligatory pro and con quotations, refers to a couple key surveys of public attitudes about GMOs, mentions some recent epidemiological work, and ends with a boilerplate statement from Monsanto proclaiming the utter adequacy of the status quo ante to ensure "food safety" as supported by "satisfied" experts in...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...